Search
MRK.US: Keytruda survival data in strongly PD-L1 +ve lung cancer may cast a transient shadow over Op
- Amit Roy
- Oct 26, 2015
- 1 min read
Can Merck undercut Bristol in the PD-1 lung cancer market?
While Opdivo currently has the best label of the newly approved anti PD-1s in 2nd line lung cancer, Merck may be able to undercut the market if they choose
Comentarios